1-[4-(1-{1,4-dioxaspiro[4.5]decan-8-yl}-4-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-3-methylurea

• ChemBase ID: 73140
• Molecular Formular: C27H33N7O4
• Molecular Mass: 519.59542
• Monoisotopic Mass: 519.25940257
• SMILES: c1(nc(nc2c1cnn2C1CCC2(CC1)OCCO2)c1ccc(cc1)NC(=O)NC)N1CC2CCC(O2)C1
• Canonical SMILES: CNC(=O)Nc1ccc(cc1)c1nc(N2CC3CCC(C2)O3)c2c(n1)n(nc2)C1CCC2(CC1)OCCO2
• InChI: InChI=1S/C27H33N7O4/c1-28-26(35)30-18-4-2-17(3-5-18)23-31-24(33-15-20-6-7-21(16-33)38-20)22-14-29-34(25(22)32-23)19-8-10-27(11-9-19)36-12-13-37-27/h2-5,14,19-21H,6-13,15-16H2,1H3,(H2,28,30,35)
• InChIKey: QLHHRYZMBGPBJG-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[4-(1-{1,4-dioxaspiro[4.5]decan-8-yl}-4-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-3-methylurea
• IUPAC Traditional name: 1-[4-(1-{1,4-dioxaspiro[4.5]decan-8-yl}-4-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-3-methylurea
• Synonyms: WYE-125132

Database IDs

• CAS Number: 1144068-46-1
• PubChem SID: 162038060
• PubChem CID: 25260757

CALCULATED PROPERTIES

• Acid pKa: 13.050391
• H Acceptors: 8
• H Donor: 2
• LogD (pH = 5.5): 3.145509
• LogD (pH = 7.4): 3.4426246
• Log P: 3.4481144
• Molar Refractivity: 164.3567 cm^3
• Polarizability: 54.508152 Å^3
• Polar Surface Area: 115.66 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: false

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: mTOR

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2661

Research Area

• Description: Cancer

Biological Activity

• Description: WYE-125132 is a highly potent, ATP-competitive and specific mTOR inhibitor with IC50 of 0.19 nM.
• Targets: mTOR
• IC50: 0.19 nM ^[1]
• In Vitro: WYE-125132 potently and ATP-competitively inhibits recombinant mTOR kinase with IC50 of 0.19 nM and also shows the high selectivity over various PI3Ks and a panel of 230 protein kinases. ^[1] In vitro, WYE-125132 exhibits a significant anti-proliferative activity against a panel of tumor cell lines with IC50 ranging from 2 nM (LNCap) to 380 nM (HTC116). Besides, WYE-125132 also causes cell cycle progression, induction of apoptosis, and inhibition of protein synthesis and cell size. ^[1] WYE-125132 results in a significant reduction in the synthesis of pre-tRNA^Leu by 72%, 80%, and 53% in actively proliferating cells of MG63, MDA361, and HEK293, respectively by inhibiting mTORC1. Moreover, WYE-125132 is also found to induce the dephosphorylation of Maf1 (negative regulator of Pol III transcription) and its accumulation in the nucleus. ^[2]
• In Vivo: WYE-125132 (5 mg/kg p.o.) produces significant antitumor activity and causes dose-dependent tumor growth delay in the PI3K/mTOR- and HER2-hyperactive MDA361 tumor model. In addition, WYE-125132 also shows potent antitumor efficacy in the PTEN-null glioma U87MG, non–small cell lung cancer H1975 and A549 models. ^[1]
• Features: WYE-125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor.

Combination Therapy

• Description: Combination therapy of WYE-125132 (50 mg/kg) and bevacizumab (200 μg/mouse) leads to a more significant tumor regression than single medication and thus forces tumors to continually shrink over the course of therapy. ^[1]

Protocol

• Protocol: Kinase Assay ^[1]
• Kinase assays: mTOR enzyme assays via dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA), ATP matrix assays, and mTOR immune-complex kinase assays are performed as follows. The endogenous TOR of LNCap cell lysate is immunoprecipitated by anti-FRAP/TOR (N-19). Cell lysate (1.0 mg) is mixed with 4 μg antibody coupled to protein-G/A agarose in 1 mL lysis buffer. The immune-complexes are washed sequentially with lysis buffer, lysis buffer plus 500 mM KCl, and kinase buffer wash. The immune-complexes are subjected to kinase reaction for 30 minutes at 30 °C in a final volume of 50 μL containing 10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, and 0.5 μM microcystin LR, 1 mM DTT, 10 mM MnCl₂, 100 μM ATP, 1 μg His6-S6K or 1 μg His6-4EBP1. Kinase reactions (immune-complex and purified enzymes) are terminated by NuPAGE LDS sample buffer and resolved in a 4–12% NuPAGE Bis-Tris gel for Western blotting with anti-P(T389)-p70S6K and anti-P(T46)-4EBP1, anti-FRAP/TOR (N-19), anti-FLAG M2, and anti-His6 (Clone His-1). In the radioactive assay, 10 μCi [γ-^32P]ATP (3000 Ci/mmol) and 100 μM cold ATP are used. ^32P-labeled products are resolved by SDS–PAGE and subjected to autoradiogram to Kodak X-ray films.
• Protocol: Cell Assay ^[1]
• Cell Lines: MDA-MB-361, MDA-MB-231, MDA-MB-468, BT549, LNCap, A549, H1975, H157, H460, U87MG, A498, 786-O, HCT116, MG63, Rat1, HEK293, and HeLa
• Concentrations: 0 to 10 μM
• Incubation Time: 24 hours
• Methods: Cell lines of MDA-MB-361, MDA-MB-231, MDA-MB-468, BT549, LNCap, A549, H1975, H157, H460, U87MG, A498, 786-O, HCT116, MG63, Rat1, HEK293, and HeLa are obtained from the American Type Culture Collection. Cell growth assays and IC50 determination are described as follows. For tumor cell growth assays, cells are plated in 96-well culture plates at 1000 to 3000 cells per well for 24 hours, treated with DMSO or various doses of WYE-125132. Viable cell densities are determined three days later by MTS assay employing an assay kit following the kit assay protocol. The effect of each treatment is calculated as percent of control growth relative to the DMSO-treated cells grown in the same culture plate. Inhibitor dose response curves are plotted for determination of IC50 values.
• Protocol: Animal Study ^[1]
• Animal Models: U87MG, MDA361, H1975, A549, A498, and 786-O cells are injected s.c. into the right flank of CD1 nu/nu mice.
• Formulation: WYE-125132 is dissolved in 5% ethanol, 2% Tween 80, and 5% polyethylene glycol-400.
• Doses: ≤50 mg/kg
• Administration: Administered via i.v. or p.o.

References

• References: [1] Yu K, et al. Cancer Res. 2010, 70(2), 621-631.
• References: [2] Shor B, et al. J Biol Chem. 2010, 285(20), 15380-15392.

REFERENCES

• Yu K, et al. Cancer Res. 2010, 70(2), 621-631.
• Shor B, et al. J Biol Chem. 2010, 285(20), 15380-15392.